Skip to content
Abbott logo

Abbott India

ABBOTINDIA NSE
₹27,120.00 No trade today
P/E
35.69
View as Markdown
MCP
Close 4 Nov 2026 ₹27,120.00 −2,335.00 −7.93% 1Y
Start ₹29,455.00

Key Fundamentals

MidcapPharmaceuticals & BiotechnologyHealthcare

Price-based figures as of · EPS basis: Standalone · TTM

ROCE
44.80%
Debt to Equity
0.04
EPS (TTM)
₹759.88
Book Value
₹2,246.68
Market Cap
—
P/E (TTM)
35.69
P/B
12.07
ROE
34.40%
Dividend Yield
2.54%
EBITDA
₹2,180 Cr
52W High
₹30,655.00
52W Low
₹24,650.00
Volume
0

Peer Comparison

Healthcare › Pharmaceuticals

Abbott peer comparison
Sun Pharma
₹1,773.4038.81₹4,29,049 Cr4.770.90%16.00%20.50%₹61,631 Cr₹10,987 Cr
Divis Laboratories
₹10,037.5091.10₹2,65,269 Cr15.900.30%16.50%22.00%₹11,230 Cr₹2,925 Cr
Torrent Pharmaceuticals
₹4,738.5078.61₹1,77,061 Cr9.810.82%27.40%15.20%₹17,400 Cr₹2,099 Cr
Zydus Life Science
₹1,188.1026.44₹1,25,446 Cr4.370.08%21.20%21.10%₹28,592 Cr₹4,593 Cr
Laurus Labs
₹2,323.80114.81₹1,25,228 Cr20.720.04%18.30%17.80%₹7,270 Cr₹1,090 Cr
Dr Reddys Laboratories
₹1,374.0035.59₹1,14,543 Cr2.960.58%11.20%13.00%₹33,228 Cr₹3,184 Cr
Cipla
₹1,402.0033.59₹1,12,454 Cr3.200.93%11.60%15.50%₹28,324 Cr₹3,356 Cr
Abbott (this company)
₹27,120.0035.69₹55,068 Cr12.072.54%34.40%44.80%₹7,004 Cr₹1,615 Cr
Median 8 companies₹2,048.6037.25₹1,25,337 Cr7.290.70%17.40%19.15%₹22,862 Cr₹3,055 Cr

Comparable companies in the same industry. Market cap, P/E and P/B use the latest price; other metrics are as reported in filings. A dash means the figure is not published for that company.

Tapetide Score

Data-driven rating, 0–100, as of . How it works →

Overall score

54 Average

Data confidence 100/100

Category scores

Quality
74
Strong
Returns, margins, earnings quality 22% weight
Valuation
66
Good
Cheap vs sector & own history 24% weight
Growth
14
Poor
Sales & profit trajectory 9% weight
Financial Health
86
Strong
Solvency, leverage, coverage 9% weight
Momentum
19
Poor
Trend strength, vol-adjusted 12% weight
Ownership
50
Average
FII/DII/promoter flows 24% weight

The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.

Key Insights

Strengths

3
  • Company is almost debt free.
  • Company has a good return on equity (ROE) track record: 3 Years ROE 34.9%
  • Company has been maintaining a healthy dividend payout of 77.9%

Weaknesses

2
  • Stock is trading at 11.6 times its book value
  • The company has delivered a poor sales growth of 9.96% over past five years.

Technical Indicators

Technical signals: verdict and indicator counts
GroupSignalBearishNeutralBullish
OverallStrong Bullish2512
OscillatorsNeutral252
Moving AveragesStrong Bullish0010

Key readings

RSI (14)
61.47
Neutral
MACD (12,26,9)
−39.19
Bullish
SMA (50)
26,147.70
Bullish
SMA (200)
26,628.50
Bullish

As of

Analyst Rating

Based on 7 analysts
BUY86%

6 of 7 analysts rate Buy, 1 Hold, 0 Sell.

As of

BUY
6
86%
HOLD
1
14%
SELL
0
0%

Growth Rate

From the financial statements below. 10Y, 5Y, 3Y: compound annual growth to Mar 2026; 1Y: fiscal year to Mar 2026 against Mar 2025; TTM: four quarters to Jun 2026 against Jun 2025.

Revenue

Revenue growth by window
10Y+10.24%
5Y+9.96%
3Y+9.01%
1Y+8.11%
TTM+6.30%

Net profit

Net profit growth by window
10Y+19.79%
5Y+17.57%
3Y+17.82%
1Y+9.76%
TTM+11.15%

Operating cash flow

Operating cash flow growth by window
10Y+18.14%
5Y+12.65%
3Y+13.88%
1Y+30.34%
TTM—

TTM: Reported once a year, so there is no trailing-twelve-month figure.

Operating margin· change in pp

Operating margin growth by window
10Y+13.35 pp
5Y+5.92 pp
3Y+4.76 pp
1Y+0.86 pp
TTM+1.53 pp

Revenue by year

Revenue by year, ₹ crore
Mar 2017₹2,903 Cr
Mar 2018₹3,298 Cr
Mar 2019₹3,679 Cr
Mar 2020₹4,093 Cr
Mar 2021₹4,310 Cr
Mar 2022₹4,919 Cr
Mar 2023₹5,349 Cr
Mar 2024₹5,849 Cr
Mar 2025₹6,409 Cr
Mar 2026₹6,929 Cr

Net profit by year

Net profit by year, ₹ crore
Mar 2017₹277 Cr
Mar 2018₹401 Cr
Mar 2019₹450 Cr
Mar 2020₹593 Cr
Mar 2021₹691 Cr
Mar 2022₹799 Cr
Mar 2023₹949 Cr
Mar 2024₹1,201 Cr
Mar 2025₹1,414 Cr
Mar 2026₹1,552 Cr

Analyst Forecasts

Forecast For
Sep 26 consensus · EBITDA
₹560 Cr −6.3% vs Jun 26
Reported High Mean Low

AI Analysis — Bull vs Bear

Figures as of 4 Nov 2026
AI opinion · based on fundamentals
Risk medium

Abbott India Ltd trades at ₹27,120 as of 2026-11-04 with a market cap of ₹55,068 Cr, commanding a PE of 35.69x and ROE of 32.51%. The company operates with near-zero debt (debt-to-equity of 0.04) and has compounded profits at 20% over the past decade, though recent revenue growth has moderated to 6% on a TTM basis.

Bull Case 7
  • Virtually debt-free balance sheet with a debt-to-equity ratio of just 0.04, providing significant financial flexibility and resilience against economic downturns.
  • Exceptional return on equity of 32.51% and ROCE of 41.87% as of 2026-11-04, indicating highly efficient capital deployment relative to most peers in the Indian pharmaceutical space.
  • Strong long-term profit compounding at 20% over 10 years and 18% over 3 years, demonstrating sustained earnings growth well above revenue growth through margin expansion.
  • Consistent ROE track record averaging 31% over 10 years and 35% over the last 3 years, reflecting durable competitive advantages in its therapeutic segments.
  • Healthy dividend payout ratio of 77.9% coupled with a dividend yield of 2.54%, offering meaningful cash returns to shareholders — uncommon among growth-oriented pharma companies.
  • Profit growth has consistently outpaced sales growth (17% vs 10% compounded over 5 years), signalling improving operating leverage and pricing power in its product portfolio.
  • The stock is trading about 11.5% below its 52-week high of ₹30,655, having found support above the 52-week low of ₹24,650, suggesting some valuation correction has already occurred.
Bear Case 7
  • Revenue growth has been tepid at 10% compounded over 5 years and has further decelerated to just 6% on a TTM basis, raising questions about the company's ability to sustain premium valuations.
  • At a trailing PE of 35.69x, the valuation is elevated relative to the TTM EPS growth of 11%, implying a PEG ratio well above 1x and suggesting the market is pricing in acceleration that has yet to materialise.
  • The stock has delivered a negative 1-year return of -12% and a modest 5-year CAGR of only 4%, indicating that market returns have significantly lagged the company's underlying profit growth.
  • TTM profit growth of 11% represents a notable deceleration from the 3-year compounded rate of 18% and the 10-year rate of 20%, suggesting a potential growth plateau.
  • Sales growth compounded at only 9% over 3 years, below the 10-year average of 10%, indicating the top-line trajectory is flattening rather than accelerating.
  • With a market cap of ₹55,068 Cr and EPS of ₹759.88, the company must sustain high-teens earnings growth to justify its current multiple — any margin compression could trigger a significant de-rating.
  • The 3-year stock CAGR of just 5% versus 18% profit compounding over the same period suggests the market has already been re-rating the stock downward, and further multiple contraction remains a risk.

This is AI-generated analysis, not financial advice. Do your own due diligence.

AI News Digest

28d ago

TL;DR: The only recent news for Abbott India is the Company Secretary's resignation, a routine compliance-level change that doesn't signal anything about the business. These articles contain no information on earnings, product launches, pricing or regulatory matters, so they don't show whether things are getting better or worse. The main thing to watch is how smoothly the company names a new Company Secretary and Compliance Officer before October 28, 2026. Upcoming quarterly results and any drug price control (NLEM/DPCO) changes will matter more for the stock.

Neutral 1
  • Company Secretary Sangeeta Shetty resigns Sep 7

    Abbott India Limited accepted the resignation of Sangeeta Shetty as Company Secretary and Compliance Officer, effective October 28, 2026. This is a routine governance change with no expected effect on operations or earnings.

Quarterly Results

₹ Cr
ABBOTINDIA quarterly results, ₹ crore
Particulars Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales
1,479
1,494
1,437
1,439
1,558
1,633
1,614
1,605
1,738
1,757
1,724
1,710
1,814
Expenses
1,124
1,113
1,049
1,109
1,167
1,194
1,178
1,176
1,293
1,255
1,261
1,229
1,291
Operating Profit
355
381
388
330
391
439
436
429
446
502
463
481
522
OPM %
24%
25%
27%
23%
25%
27%
27%
27%
26%
29%
27%
28%
29%
Other Income
56
56
56
81
67
60
72
76
73
70
70
76
75
Interest
3
3
3
3
3
2
2
4
6
8
5
6
6
Depreciation
17
18
18
18
18
18
18
18
19
19
19
19
20
PBT
390
415
422
390
437
479
488
483
493
546
509
531
572
Tax %
26%
25%
26%
26%
25%
25%
26%
24%
26%
24%
26%
26%
25%
Net Profit
290
313
311
287
328
359
361
367
366
415
376
395
429
EPS (₹)
137
147
146
135
154
169
170
173
172
195
177
186
202

Profit & Loss

₹ Cr
ABBOTINDIA profit and loss, annual, ₹ crore
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales
2,289
2,614
2,903
3,298
3,679
4,093
4,310
4,919
5,349
5,849
6,409
6,929
7,004
Expenses
1,977
2,250
2,505
2,774
3,074
3,336
3,388
3,832
4,143
4,396
4,714
5,037
5,035
Operating Profit
312
365
398
525
605
757
922
1,088
1,206
1,453
1,695
1,892
1,969
OPM %
14%
14%
14%
16%
16%
18%
21%
22%
23%
25%
26%
27%
28%
Other Income
48
50
57
117
113
114
81
77
154
248
275
288
291
Interest
0
3
2
4
2
9
18
19
16
12
11
25
25
Depreciation
15
14
16
16
17
60
58
66
70
71
72
76
76
PBT
344
398
436
621
699
803
926
1,080
1,274
1,618
1,887
2,079
2,158
Tax %
34%
36%
37%
35%
36%
26%
25%
26%
25%
26%
25%
25%
—
Net Profit
229
255
277
401
450
593
691
799
949
1,201
1,414
1,552
1,615
EPS (₹)
108
120
130
189
212
279
325
376
447
565
666
730
760
Div. Payout %
29%
29%
31%
29%
31%
90%
85%
73%
73%
73%
71%
90%
—

Balance Sheet

₹ Cr
ABBOTINDIA balance sheet, annual, ₹ crore
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
21
21
21
21
21
21
21
21
21
21
21
21
Reserves
916
1,174
1,366
1,672
1,987
2,410
2,581
2,799
3,167
3,678
4,212
4,753
Borrowings
0
0
0
0
0
175
153
152
113
83
197
172
Other Liabilities
436
421
679
723
932
940
1,086
1,253
1,254
1,411
1,487
1,556
Total Liabilities
1,374
1,616
2,066
2,416
2,941
3,547
3,840
4,224
4,556
5,193
5,917
6,502
Fixed Assets
96
108
110
81
105
270
251
271
237
225
336
331
CWIP
4
3
6
2
1
2
1
1
4
10
18
6
Investments
0
0
0
0
0
0
0
0
0
0
0
0
Other Assets
1,274
1,505
1,950
2,333
2,835
3,275
3,589
3,952
4,315
4,958
5,563
6,165
Total Assets
1,374
1,616
2,066
2,416
2,941
3,547
3,840
4,224
4,556
5,193
5,917
6,502

Cash Flow

₹ Cr
ABBOTINDIA cash flow, annual, ₹ crore
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
215
249
307
153
499
626
727
948
893
1,213
1,012
1,319
Investing
−187
−77
−155
−215
−257
−401
−72
−396
−148
−416
182
−371
Financing
−58
−80
−90
−102
−143
−217
−582
−637
−639
−745
−925
−1,066
Net Cash Flow
−30
91
62
−165
99
8
73
−86
107
52
269
−118
Free Cash Flow
199
226
287
180
504
611
704
904
860
1,165
960
1,307
CFO/EBITDA
106
109
117
68
125
113
104
114
102
111
86
98

Ratios

ABBOTINDIA financial ratios, annual
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
21
20
22
29
27
28
21
21
22
20
22
19
Inventory Days
107
91
107
112
106
83
110
94
80
70
92
94
Days Payable
54
56
101
92
116
104
116
122
109
114
110
109
Cash Conversion Cycle
74
54
28
49
17
8
14
−6
−8
−24
3
3
Working Capital Days
30
32
21
63
22
10
4
−7
−8
−14
99
2
ROCE %
40%
38%
34%
41%
37%
35%
35%
38%
41%
46%
46%
45%

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Abbott insights

61 extracted metrics across FY10–FY27.

Shareholding Pattern

As of Sep 2026

  • Promoters 74.99%
  • Public 13.19%
  • DIIs 8.99%
  • Others 2.44%
  • FIIs 0.40%

No promoter shares pledged as of 14 Oct 2026

Change vs previous quarter

Not shown for some quarters: Others. Not available separately for this quarter: the shareholding filing gives Public and Others as one figure, shown under Public, so Others is left blank rather than estimated.

Documents

Frequently Asked Questions about Abbott India

What does Abbott India Ltd do?
Abbott India Ltd is one of the leading multinational pharmaceutical companies in India and sells its products through independent distributors primarily within India. It was established in 1944.
Where is Abbott India Ltd (ABBOTINDIA) listed?
Abbott India Ltd trades as ABBOTINDIA on the NSE and under code 500488 on the BSE.
Which sector does Abbott India Ltd belong to?
Abbott India Ltd is classified under the Healthcare sector, in the Pharmaceuticals industry.
What is the PE ratio of Abbott India Ltd?
Abbott India Ltd trades at a PE ratio of 35.69 as of 4 Nov 2026, on earnings per share of ₹759.88, against a book value of ₹2,246.68 per share.
What is the 52-week high and low of Abbott India Ltd?
Over the last 52 weeks Abbott India Ltd has traded between ₹24,650 and ₹30,655 as of 4 Nov 2026.
Does Abbott India Ltd pay dividends?
Abbott India Ltd has a dividend yield of 2.54%.
What is the Return on Equity (ROE) of Abbott India Ltd?
Abbott India Ltd reported a return on equity of 34.40%. Its debt-to-equity ratio is 0.04.

Company Information

Abbott India Ltd is one of the leading multinational pharmaceutical companies in India and sells its products through independent distributors primarily within India. It was established in 1944.

Website abbott.co.in
CEO Mr. Kartik Rajendran
Employees 3,659
Listed 8 Jan 2010
Face Value ₹10

For AI agents and developers

Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/ABBOTINDIA.md for Abbott India Ltd: dated key facts, then this page's sections in order: latest price, key fundamentals, peer comparison, the Tapetide Score, technical indicators, analyst ratings, growth rates, analyst forecasts, the AI analysis and news digest (labelled as AI-generated), financial statements, shareholding pattern, documents and the FAQ.

Append .md to any Tapetide URL for the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live, structured queries instead of documents, use our Indian stock market MCP server.

Explore More

More Pharma stocks → FII DII DataStock ScreenerNifty 50 HeatmapF&O Ban ListFII and DII flows, month by monthHow Tapetide Scores changed, month by monthStocks mutual funds are buying, month by month